10x Genomics Projects Sequential Revenue Growth Despite Ongoing Operating Losses

Q3 Financials Show Sequential Revenue Stability Amid Lower Operating Loss

10x Genomics (NASDAQ: TXG) reported third quarter 2025 financial results that highlight disciplined cost controls, resilient core business demand, and a robust cash position—even as challenges remain. Revenue for the quarter landed at $149.0 million, down modestly year-over-year (by 2%) but up 2% from Q2 2025 if one-time royalties from the prior quarter are excluded. Net loss and operating loss both improved compared to the previous year, signaling tightening operational discipline.

Innovation-Fueled Demand: Next-Gen Product Launches and Market Enthusiasm

Despite modest headline revenue pressure, 10x Genomics continued its push for product innovation—shipping the Chromium Flex and launching Xenium Protein, an industry-first fully integrated workflow for simultaneous RNA and protein detection. These new launches bolster the company’s positioning in the competitive life sciences sector and align with growing market enthusiasm for single cell and spatial biology solutions, according to CEO Serge Saxonov.

Strong Balance Sheet: Cash Position Surges By $35 Million in the Quarter

The company ended the third quarter with $482.1 million in cash, cash equivalents, and marketable securities, marking a $35 million increase versus the previous quarter. With this, management reaffirmed confidence in navigating current industry and macroeconomic uncertainty, maintaining a buffer to fund innovation and strategic priorities.

Expense Reductions Drive Narrower Net and Operating Losses

Third quarter operating expenses dropped to $132.5 million, down 10% from a year ago, primarily on lower personnel and legal expenses. Gross margin, at 67%, dipped slightly due to product mix and higher inventory write-downs, but was partially offset by reductions in royalties and warranty costs. Both net loss and operating loss showed year-over-year improvement, reflecting greater cost control without sacrificing research intensity or growth.

Geographic and Product Breakdown Highlights Steady U.S. and APAC Performance

U.S. revenue came in at $77.25 million for the quarter, while Asia-Pacific—particularly China—remained steady at $15.19 million. Notably, consumables (especially Chromium and Spatial) continued to account for the bulk of recurring revenue, offsetting softer demand for instruments in the same period.

Guidance Suggests Sequential Growth—But Year-Over-Year Pressure Remains

Looking ahead, 10x Genomics projects Q4 2025 revenue between $154 million and $158 million, reflecting an expected 5% sequential increase but a 6% decline versus the same quarter last year. This mixed picture suggests underlying growth momentum driven by innovation, while broader market factors may continue to temper year-over-year comparisons in the near term.

Investor Takeaway: Solid Foundation Amid Mixed Trends

While top-line growth is constrained by softness in instrument sales and competitive pressures, 10x Genomics is strengthening its financial foundation with robust cash reserves and cost control. Innovations like Chromium Flex and Xenium Protein may help catalyze future growth, but the guidance and recent results signal the company is balancing cautious optimism with prudent financial management. For investors, this mix of disciplined expense reduction and ongoing product launches could prove pivotal as 10x Genomics works to regain sustained revenue acceleration and eventual profitability.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI